A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
University College, London
University of Pittsburgh
Pfizer
Pfizer
Zealand University Hospital
City of Hope Medical Center
Novartis
Mirati Therapeutics Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
Compugen Ltd